UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 UNDER
THE SECURITIES EXCHANGE ACT OF 1934

For the month of August 2026

Commission File Number: 001-39173

NovaBridge Biosciences

2440 Research Boulevard, Suite 400
Rockville, MD 20850
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

On August 20, 2026, NovaBridge Biosciences issued an investor presentation, a copy of which is furnished herewith as Exhibit 99.1.

EXHIBIT INDEX

Exhibit No.	Description
99.1	Investor Presentation - August 20, 2026

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

NovaBridge Biosciences

By : /s/ Kyler Lei
Name : Kyler Lei
Title : Chief Financial Officer

Date: August 20, 2026


NovaBridge
Company Presentation
NASDAQ: NBP
August 2026

Disclaimer

This presentation has been prepared by NovaBridge Biosciences (the “Company”) solely for informational purposes. Certain of the information included herein was obtained from various sources, including certain third parties, and has not been independently verified by the Company. By viewing or accessing the information contained in this presentation, you hereby acknowledge and agree that no representations, warranties, or undertakings, express or implied, are made by the Company or any of its directors, shareholders, employees, agents, affiliates, advisors, or representatives (the “Relevant Persons”) as to, and no reliance should be placed on the truth, accuracy, fairness, completeness, or reasonableness of the information or opinions presented or contained in, and omission from, this presentation. None of the Relevant Persons shall be responsible or liable whatsoever (in negligence or otherwise) for any loss, howsoever arising from any information presented or contained in this presentation or otherwise arising in connection with the presentation, except to the extent required by applicable law. The information presented or contained in this presentation speaks only as of the date hereof and is subject to change without notice.

This presentation includes statistical and other industry and market data that we obtained from industry publications and research, surveys, and studies conducted by third parties, and our own estimates of potential market opportunities. All of the market data used in this presentation involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such data. Industry publications and third-party research, surveys and studies generally indicate that their information has been obtained from sources believed to be reliable, although they do not guarantee, and we have not independently verified, the accuracy or completeness of such information. Our estimates of the potential market opportunities for our product candidates include several key assumptions based on our industry knowledge, industry publications, third-party research, and other surveys, which may be based on a small sample size and may fail to accurately reflect market opportunities. While we believe that our internal assumptions are reasonable, no independent source has verified such assumptions.

We own or have rights to trademarks or trade names that we use in conjunction with the operation of our business and that appear in this presentation. This presentation also contains references to trademarks and trade names belonging to other entities. All rights to the trademarks, copyrights, logos and other intellectual property listed herein belong to their respective owners and our use or display thereof does not imply an affiliation with, or endorsement by, any other entities.

This presentation contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “future,” “promising,” “may,” “plans,” “potential,” “will,” “could position,” “promise,” “advance,” “target,” “design,” “strategy,” “pipeline,” and “project,” and similar terms or the negative thereof. Statements that are not historical facts, including statements about the Company’s beliefs and expectations, are forward-looking statements. The forward-looking statements in this presentation include, without limitation, statements regarding the following: the Company’s pipeline and capital strategy; the design and potential benefits, advantages, promise, attributes, and target usage of givastomig, ragistomig, ulilediimab and VIS-101; the impact of independent evaluations of our clinical trials results; the reliability and reproducibility of comparative clinical data; the projected development and advancement of the Company’s portfolio and anticipated clinical milestones, results and related timing; the Company’s expectation regarding the potential market opportunity of gastric cancer, pancreatic ductal adenocarcinoma, cholangiocarcinoma, neovascular age-related macular degeneration and diabetic macular edema; the market opportunity and the Company’s potential next steps (including the potential expansion, differentiation, or commercialization) for givastomig, ragistomig, ulilediimab and VIS-101; estimated future revenues from the Company’s product candidates if approved; the Company’s expectations regarding the impact of data from past, ongoing and future studies and trials; the benefits of the Company’s collaboration with development partners; the timing and progress of studies (including with respect to patient enrollment and dosing); the availability of data and information from ongoing studies; and the Company’s expectations regarding its anticipated cash runway, potential valuations of the Company's assets and subsidiaries, the potential total addressable market of the Company's product candidates, if approved, ability to obtain financing and future use of its cash position. These forward-looking statements involve inherent risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such forward-looking statements. These risks and uncertainties include, but are not limited to, the following: the Company’s ability to demonstrate the safety and efficacy of its drug candidates; the clinical results for its drug candidates, which may or may not support further development or new drug application/biologics license application approval; the content and timing of decisions made by the relevant regulatory authorities regarding regulatory approval of the Company’s drug candidates; the Company’s ability to achieve commercial success for its product candidates, if approved; the Company’s ability to obtain and maintain protection of intellectual property for its technology and drugs; the Company’s reliance on third parties to conduct drug development, manufacturing and other services; the Company’s limited operating history and the Company’s ability to obtain additional funding for operations and to complete the development and commercialization of its drug candidates; the impact of macroeconomic conditions, including inflation, tariffs, volatile interest rates, regulatory uncertainty, potential government shutdowns, volatility in the capital markets, and regional and other global events, including ongoing armed conflicts in different regions of the world; and discussions of potential risks, uncertainties, and other important factors in the Company’s most recent annual report on Form 20-F and the Company’s subsequent filings with the U.S. Securities and Exchange Commission (the “SEC”). The Company may also make written or oral forward-looking statements in its periodic reports to the SEC, in its annual report to shareholders, in press releases and other written materials, and in oral statements made by its officers, directors, or employees to third parties. All forward-looking statements are based on information currently available to the Company. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as may be required by law.

Bridging the gap between exceptional science and global patient impact

A global biotechnology company that identifies differentiated innovation and applies disciplined development, financing, and partnering strategies to create value

The Opportunity

Exceptional science is emerging worldwide, yet too many promising therapies never reach their full potential. We believe the bottleneck is not innovation, but the path to patients

NovaBridge

We identify, de-risk, and advance high-potential therapies, helping transform breakthrough innovation into meaningful patient impact

Innovation is no longer the bottleneck, translation is

2,227

New Molecule Entities are being developed in China

Up from ~78 in 2013; a 28× expansion in more than a decade

~85%

Growth from Asia

Of global innovative pipeline in 2024

46%

New Molecules from China

Of all new molecules entering human trials in H1; up from ~17% a decade ago

>$50B

China-Origin Deal Value

In 2024; a 10× increase from ~$5B in 2020, ~30% of global licensing volume

Data Source: Nature Biotechnology; McKinsey; Goldman Sachs 2025 report; Nature, Sep 2025; CBC Internal analytics

Three advantages drive NovaBridge's value-creation model

We access differentiated assets early through trusted relationships, deep networks, and on-the-ground expertise

We develop and advance assets ourselves across global markets, from IND through clinical proof-of-concept, generating the data needed to drive informed strategic decisions

We deploy capital selectively and flexibly, focusing on opportunities where our differentiated capabilities create the greatest advantage

A repeatable model for building sustainable value

Each franchise applies a disciplined approach to sourcing, development, financing, and value creation



The NovaBridge model in action: Givastomig

Rapid development and multiple pathways to value

Access

Identified a differentiated CLDN18.2 opportunity combining high-affinity target binding, broad activity across CLDN18.2 expression levels, and conditional 4-1BB activation designed to balance efficacy and safety

Development

Advanced givastomig from Phase 1b to Phase 3 readiness in approximately 18 months

77%

Confirmed ORR at 8 mg/kg in Phase 1b

Optionality

Created multiple pathways for value realization through regulatory progress, financing discussions, and strategic partnering opportunities

$5B+

Peak sales potential across indications

Givastomig demonstrates NovaBridge's ability to execute efficient clinical development strategies and advance programs toward major value inflection points with multiple options for value realization

Givastomig data cut-off Dec 2, 2025. Peak sales potential reflects management estimates of the global opportunity.

Givastomig: Exceptional clinical execution proof point

Speed to Phase 3: 18 months from Phase 1b data (n=17) to Phase 3 initiation



Givastomig: Differentiated clinical profile

Clinical differentiation: Deep, durable activity in Phase 1b first-line gastroesophageal adenocarcinoma, with nivolumab and chemotherapy

High response rates

77%
Confirmed ORR at 8 mg/kg

73%
ORR incl. uPR at 12 mg/kg

96-100%
Disease control rate across dose cohorts

Compares favorably with current 1L benchmarks, with room for maturation at 12 mg/kg.

Broad biomarker activity

ORR preserved across CLDN18.2 strata

Claudin 18.2 levels	8 mg/kg 12 mg/kg
CLDN18.2 ≥75%	76% / 67%
CLDN18.2 1-74%	78% / 79%

Activity extends well beyond CLDN18.2-high patients, supporting a materially broader addressable population.

Durable disease control

>15 mo
Median DoR at 8 mg/kg

16.9 mo
Median PFS at 8 mg/kg

OS NR
Median OS not reached; 12-month OS 69%

Deep tumor shrinkage, sustained PFS and immature but encouraging OS.

Givastomig data cut-off December 2, 2026.

Givastomig: $5B+ peak sales potential across indications, if approved

Expanding from the 1L GEA to BTC and PDAC

	Indication expansion options	Regimen	Pivotal start	Notes	Peak sales
GEA	**HER2- | 1L metastatic | CLDN >=1, PD-L1 >=1**	Giva + nivo + chemo	2026	Current lead indication	$2B+
	HER2- | 1L metastatic | CLDN 1-74, PD-L1 <1	Giva + chemo	2029	Expedites recruitment in companion study	
	HER2- | 1L metastatic | CLDN <1, PD-L1 <1	Giva + chemo	2028	Builds preliminary data in companion study	$2B+
	HER2- | 1L locally advanced resectable	Giva + durva + FLOT	2028	Two IITs supported by leading KOLs	
	HER2+ | 2L, CLDN >=1	Giva + Enhertu	2028	Combination with an approved ADC backbone	
BTC	1L metastatic | CLDN >=1	Giva + durva + gem/cis	2027	Cohort recruiting in Phase 1b	$0.5B+
PDAC	1L metastatic | CLDN >=1	Giva + gem/Abraxane	2028	Cohort recruiting in Phase 1b	$1B+

$5B+
Peak sales across all indications, if approved

Peak sales potential reflects management estimates of the global opportunity. GEC = gastroesophageal adenocarcinoma; BTC = biliary tract cancer; PDAC = pancreatic ductal adenocarcinoma; IIT = investigator-initiated trial.

The NovaBridge model in action: Visara

Target-product-profile driven asset sourcing, world-class expertise, and franchise creation in ophthalmology

Access

Identified high-conviction opportunity with differentiated ophthalmology assets

Applied a clear target product profile to identify the lead asset in neovascular retina disease focused on durability, accessibility, and unmet patient need to build an ophthalmology franchise with other high unmet assets in process

Multiple assets identified

Differentiated ophthalmology assets sourced and/or secured

Development

Built a world-class front and back of the eye experienced team to accelerate global development

Assembled experienced ophthalmology leaders with global development expertise, including China execution capabilities, to advance programs rapidly while maintaining global quality standards

Global expert team

World-class team with global execution expertise

Optionality

Multiple pathways to value creation

Structured partnerships, financing solutions, and development strategies that support franchise growth while preserving future upside.

Multiple paths

Financing and partnership pathways preserved

Visara demonstrates how NovaBridge combines differentiated asset sourcing with the ability to build high-caliber teams around compelling therapeutic opportunities

The first dual-targeting peptibody candidate designed to treat ocular neovascularization

VIS-101

- 2X the binding sites for VEGF-A
- 2X the binding sites for ANG-2
- Improved inhibitory activity compared to the industry leading product
- Long vitreous half-life of ~8-12 days*



Potential Next Generation SOC in nAMD, DME, RVO

Potential to be best-in-class anti-VEGF/Ang-2 agent with **LONGER DURABILITY** and **LESS FREQUENT DOSING**

** Assumes 6mg or 9mg dose*

Visara: Lead retinal asset with an expanding pipeline

Front and back of the eye, targeting aggregate annual markets of more than $10 billion

VIS-101

Tetravalent VEGF / ANG-2 peptibody
Phase 2b expected to start in 2H 2026

AMD | DME | RVO

Extended durability by design — materially fewer injections than the current anti-VEGF / ANG-2 standard of care.

Best-in-class potential with prolonged durability

$8Bn
Projected annual market

>90%
Probability of technical success

Late-stage, de-risked and financed
China rights sublicensed to Everest Medicines to fund Phase 2b expected to start in 2H 2026

Pipeline Expansion

Two additional promising pipeline assets to replicate success

VIS-102

Term sheet signed

A potential best-in-class biologic in a rare disease indication. Target, terms and economics undisclosed.

VIS-103

Under evaluation

A potential first -in-class AND best-in-class biologic in a rare disease indication. Details withheld while negotiations continue.

Full disclosure will follow on completion of the respective transactions

AMD = age-related macular degeneration; DME = diabetic macular oedema; RVO = retinal vein occlusion. Programme details for assets under negotiation are withheld. Market size reflects management estimates.

Extending the same repeatable model into new areas

Future growth built around the same principles: unmet need, differentiated assets, exceptional talent, and flexible value creation

Europe

POSITIONING

Applying the NovaBridge model to underserved opportunities in Europe

KEY MILESTONES

Partnership discussions with major European pharmaceutical companies

Women's Health

POSITIONING

Applying a target-product-profile driven sourcing strategy in a high unmet need area

KEY MILESTONES

700+ assets screened, 2 opportunities under active evaluation

In late-stage discussions with financing partners and potential strategic partners.

Our vision and growth path

Creating a repeatable engine for turning exceptional science into patient impact

Establish the foundation
Next 12 months

- Expand clinical and BD capabilities
- Advance givastomig and Visara

Two scaled franchises

Scale the playbook
Next 1-5 years

Hub level
- Source new assets
- Launch new spokes

Spokes level
- New clinical and commercial milestones
- First revenue generating assets
- Additional Value realization events

Repeatable growth engine

Sustainable company
Next 5-10 years

Group level
- Diversified 10+ asset portfolio
- Selective commercialization
- Partner of choice
- Sustainable profitability
- Trusted public company

A sustainable biotechnology company

NovaBridge at a glance

NBP
Nasdaq ticker
Publicly traded biotechnology company

Global
Capabilities
United States, Europe and Asia

2
Proofs of execution
Givastomig and VIS-101

3
Clinical-stage assets
Programs in active development

~$216M
Cash & equivalents
Incl. short-term investments[1]

NONE
Debt
Debt-free balance sheet[1]

700
Assets screened
Disciplined sourcing process

Multiple
Value-creation pathways
Development, partnering, financing, affiliate formation

1. NovaBridge information reported for June 30, 2026 financials (including $191 million Cash and cash equivalents, ~$25 million investments at fair value, equity securities

A differentiated clinical pipeline built on our global platform

ASSET/ TARGET	INDICATION(S)	REGIMEN	PHASE 1	PHASE 2	REGISTRATIONAL/ PHASE 3	NCT #	MILESTONES
Givastomig[1,2] CLDN18.2 X 4-1BB	1L GEA	Giva + Chemo + Nivo vs. Chemo + Nivo	CLDN18.2 Positive/PD-L1 Positive			NA	Initiate as early as YE 2026
		Giva/Nivo/Chemo v. Nivo/Chemo	CLDN18.2 Positive			NCT07432295	Phase 2 data 2H 2027
		Giva + Chemo + Nivo	CLDN18.2 Positive			NCT04900818	Phase 1b data at ESMO 2026
		Giva + Chemo	CLDN18.2 Low/PD-L1 Low				Phase 1b cohort ongoing
	1L BTC	Giva + Chemo + CPI	CLDN18.2 Positive				Phase 1b cohort ongoing
	1L PDAC	Giva + Chemo	CLDN18.2 Positive				Phase 1b cohort ongoing
VIS-101 VEGF-A X ANG-2	Neovascular AMD	Mono	Phase 2b (China)				Phase 2b FPI 2H 2026 anticipate ph3 initiation 2H 2027
	DME	Mono				NCT05940428	Phase 1 complete
Ragistomig[1] PD-L1 X 4-1BB	Solid Tumors	Ragi ± PD-(L)1				NCT04762641	Partnered with ABLBio who leads development Phase 1 data at ESMO 2026
Uliledlimab CD73	NSCLC	Uli + PD-(L)1 ± Chemo	CD73 Positive			NCT06984588	Partnered with TJ Bio

1. *Givastomig also known as ABL111, ragistomig also known as ABL503*
2. *BMS agreed to manufacture, supply and grant us a license to use nivolumab (OPDIVO®) in our Phase 1 trial to evaluate givastomig's combination with nivolumab and mFOLFOX6*
3. *Trial conducted by TJ Biopharma, NCT04322006*
4. *Global rights, ex-Greater China, ex-South Korea*
5. *Global rights, ex-China*

Ongoing Clinical Trials Clinical Trials to be Initiated

Oncology Programs Ophthalmology Programs

Notes: mAb = monoclonal antibody; bsAb = bispecific antibody; 1L = first line; nivo = nivolumab; tori = toripalimab (TUOYI®); CPI = checkpoint inhibitor; GEA = gastroesophageal adenocarcinoma, including gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma; BTC = biliary tract cancer; PDAC = pancreatic ductal adenocarcinoma; NSCLC = non-small cell lung cancer; Wet AMD = wet age-related macular degeneration; DME = diabetic macular edema; FPI = first patient in; PD-(L)1 = inhibitors of PD-L1 or PD-1; CLDN18.2 = Claudin18.2; CLDN18.2 Low = CLDN18.2 < 75%; PD-L1 Low = CPS < 1

$216m in cash and investments to support strategic inflection points

Maintained a strong debt-free balance sheet with ~$216[1] million in cash and cash equivalents and investments at fair value, equity securities, as of June 30, 2026, providing runway through several important clinical and strategic inflection points, including givastomig's planned Phase 3 interim data readout in 2028.

Important clinical and strategic inflections points supported by cash runway

2026

- **GIVA:** Phase 1b dose expansion updated data at ESMO
- **GIVA:** Complete phase 2 combo study enrollment for 1L GEA
- **GIVA:** Phase 3 initiation, as early as YE26
- **RAGI:** Phase 1b topline data monotherapy study for solid tumors at ESMO
- **VIS101:** Phase 2b initiation for neovascular AMD

2027

- **GIVA:** Phase 1b readouts in 1L BTC and PDAC
- **GIVA:** Phase 2 data readout for 1L GEA
- **VIS101:** Phase 2b readout
- **VIS101:** Phase 3 initiation for neovascular AMD

2028

- **GIVA:** Phase 3 interim data readout for 1L GEA

Notes: 1. As of June 30, 2026, NovaBridge has ~$191 million Cash and cash equivalents, ~$25 million investments at fair value, equity securities. ESMO = the European Society for Medical Oncology; GIVA = givastomig; RAGI = ragistomig; GEA = gastroesophageal adenocarcinoma; BTC = biliary tract cancer; PDAC = pancreatic adenocarcinoma

VIS-101 Givastomig Ragistomig

Upcoming catalysts



Notes: 1L = first line; GEA = gastroesophageal adenocarcinoma (gastric, GEJ, esophageal); BTC = biliary tract cancer; PDAC = pancreatic ductal adenocarcinoma; NSCLC = non-small cell lung cancer; PFS = progression-free survival. Illustrative timeline reflects management's current expectations; not to scale.


NovaBridge
Thank you
www.novabridge.com
IR@novabridge.com